DEFINITIVE PROXY STATEMENT

Company

Coeptis Therapeutics Holdings, Inc.

Filed

October 11, 2022

Period of Report

November 2, 2022

Accession Number

0001213900-22-062913

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →